Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Gynecol Oncol. 2014 Mar 25;133(3):473–479. doi: 10.1016/j.ygyno.2014.03.563

Table 2. Immunohistochemistry results in high-grade serous ovarian carcinoma.

p53 MDR1 EGFR HER2 ER PR
Examined 119
(98.3%)
112
(92.6%)
111
(91.7%)
120
(99.2%)
113
(93.4%)
112
(92.6%)
Positivity 85
(71.4%)
16
(14.3%)
63
(52.1%)
82
(68.3%)
98
(86.7%)
10
(8.9%)
Staining intensity
 0 34
(28.6%)
96
(85.7%)
48
(43.2%)
38
(31.7%)
15
(13.3%)
101
(90.2%)
 1+ 1
(0.8%)
11
(9.8%)
15
(13.5%)
50
41.7%)
23
(20.4%)
1
(0.9%)
 2+ 7
(5.9%)
2
(1.8%)
33
(29.7%)
26
(21.7%)
51
(45.1%)
4
(3.6%)
 3+ 77
(64.7%)
3
(2.7%)
15
(13.5%)
6
(5.0%)
24
(21.2%)
6
(5.4%)
Percent expression
 0% 34
(28.6%)
96
(85.7%)
48
(43.2%)
38
(31.7%)
15
(13.3%)
101
(90.2%)
 1-25% 10
(8.4%)
10
(8.9%)
37
(33.3%)
37
(30.8%)
29
(25.7%)
9
(8.0%)
 26-50% 4
(3.4%)
4
(3.6%)
16
(14.4%)
20
(16.7%)
27
(23.9%)
0
(0%)
 51-75% 5
(4.2%)
1
(0.9%)
3
(2.7%)
13
(10.8%)
22
(19.5%)
2
(1.7%)
 76-100% 66
(55.5%)
1
(0.9%)
7
(6.3%)
12
(10.0%)
20
(17.7%)
0
(0%)

Positivity of immunohistochemistry results was defined as proportional expression of ≥5% and staining intensity of ≥1+. Abbreviations: MDR1, multi-drug resistance 1; EGFR, epidermal growth factor receptor, HER2, human epidermal growth factor receptor 2; ER, estrogen receptor alpha; and PR, progesterone receptor.